Thyrocare Technologies Ltd Share Price Today - Thyrocare Technologies Ltd Stock Price Live NSE/BSE

Thyrocare Technologies Ltd

NSE: THYROCARE BSE: 539871

₹400.30

(-1.00%)

Fri, 08 May 2026, 04:48 am

MTF 5xInvest in Thyrocare Technologies Ltd with 5x Leverage Buy with MTF

Market Cap64.31B

PE Ratio46.32

Dividend2.31

Health Services

Medical/Nursing Services

24.5K

Thyrocare Technologies Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
7458.49
Net Profit
90.75
P/B
7.33
Sector P/E
60.07
P/E
39.39
EV/EBITDA
17.48
Debt/Equity (Industry)
0.18
Interest Cover (Industry)
12.16
ROCE (Industry)
17.67
RONW (Industry)
14.82
ROE
16.91
ROCE
25.93
Debt/Equity
0.06
EPS (TTM)
8.93
Dividend Yield
0
Book Value
33.57
Interest Cover
39.89

Analysis

all

Pros

Dividends after 3 years are expected to be well covered by earnings (2x coverage).
Thyrocare Technologies's earnings growth is expected to exceed the India market average.
Thyrocare Technologies's earnings growth is expected to exceed the low risk savings rate of 7.2%.
Thyrocare Technologies is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
Performance (ROE) is expected to be above the current IN Healthcare industry average.

Cons

Unable to calculate sustainability of dividends as Thyrocare Technologies has not reported any payouts.
Unable to evaluate Thyrocare Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Thyrocare Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Cash flow for Thyrocare Technologies is expected to decrease over the next 2 years.
Thyrocare Technologies's earnings are expected to grow by 19.2% yearly, however this is not considered high growth (20% yearly).

Financials

Ratios

Shareholders	MAR 2026	DEC 2025	SEPT 2025	JUN 2025	MAR 2025
Promoters	60.92	60.93	71.06	71.06	71.06
FII	5.37	4.95	4.85	3.23	2.41
DII	20.99	20.51	13.47	14.54	14.97
Public	12.71	13.61	10.63	11.17	11.56
Government	0	0	0	0	0

Technical Analysis

RSI

84.85

MACD

23.15

50 DMA

390.39

200 DMA

425.17

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	520.60	455.50	427.90	390.40	362.80	325.30	260.20
Fibonacci	455.50	430.63	415.27	390.40	365.53	350.17	325.30
Camarilla	418.20	412.24	406.27	390.40	394.33	388.37	382.40

Pivots Level: Classic

+130.20

520.60

+65.10

455.50

+37.50

427.90

390.40

Pivot Point

LTP: 519.50

-27.60

362.80

-65.10

325.30

-130.20

260.20

Moving Average

SMAEMA

Period

Value

10-EMA
444.25
20-EMA
421.70
30-EMA
411.74
50-EMA
406.18
100-EMA
408.68
200-EMA
400.51

Announcement Date	Purpose	Action	Ex Date
07 May 2026	board-meetings	Accounts, Final Dividend
28 Jan 2026	board-meetings	Quarterly Results
17 Nov 2025	bonus	2:1 Bonus Issue of Equity Shares	28 Nov 2025
28 Oct 2025	bonus	Bonus issue 2:1	28 Nov 2025
14 Oct 2025	dividend	₹7.00 Dividend /Share	24 Oct 2025
24 Sept 2025	dividend	Interim Dividend - Rs. - 7	24 Oct 2025
05 Jul 2025	agm
25 Jun 2025	dividend	Final Dividend - Rs. - 21	25 Jul 2025
23 Apr 2025	dividend	₹21.00 Dividend /Share	25 Jul 2025
02 Aug 2024	agm

Thyrocare Technologies Ltd

Narayana Hrudayalaya Ltd

Apollo Hospitals Enterprise Ltd

Aster DM Healthcare Ltd

Max Healthcare Institute Ltd

Fortis Healthcare Ltd

Thyrocare Technologies Ltd About

Thyrocare Technologies operates in the healthcare industry and is involved in providing quality diagnostic services to patients, laboratories and hospitals in India.

Industry

Healthcare

Founded

2000

Headquarters

CEO

Rahul Guha

Employees

Contact

Website

http://www.thyrocare.com

ramjee.d@thyrocare.com; enquiry@thyrocare.com

Phone

91-22-27622762

Location

D-37/1 TTC Industrial Area, MIDC Turbhe, Navi Mumbai, Maharashtra, 400703

Year	History
2013	EIF acquired certain Equity Shares from Agalia. The Subsidiary commenced operations at the PET-CT centres at Navi Mumbai and conducted over 1,000 scans in the first year of operation.
2014	The Company had installed, India’s first and the world’s longest track automation system for seamless sample movements from Siemens Limited. The Company commissioned the operations in medical cyclotron facility in Navi Mumbai. The Subsidiary commenced operations at the PET-CT centres in New Delhi and Hyderabad and the PET-CT centres at New Delhi conducted over 1,000 scans in the first year of operations.
2015	The Company opened RPLs in Delhi, Coimbatore, Hyderabad and Kolkata to expand its coverage and volume of tests and samples processed daily. The Company acquired the equipment for testing of water samples and commenced operating the equipment under the brand name 'WHATERS'. The Subsidiary has completed over 10,000 scans at the PET-CT centres in New Delhi, over 10,000 scans at the PET-CT centres in Navi Mumbai from the date of inception and over 1,000 scans at the PET-CT centres in Hyderabad since inception.
2016	Thyrocare Technologies are listed and admitted to dealings on the Exchange in the list of 'B' Group Securities.
2024	Thyrocare Technologies Completed acquisition of Think Health Diagnostic Private Limited.

Client Name	Order Side	QTY	Avg Price	Date
NEO APEX VENTURE LLP	Buy	354298	1252.1	24 Oct 2025
HDFC MUTUAL FUND	Buy	443650	1252	24 Oct 2025
ICICI PRUDENTIAL MUTUAL FUND	Buy	1748600	1252	24 Oct 2025
HSBC MUTUAL FUND MIDCAP FUND	Buy	666133	1252	24 Oct 2025
ADITYA BIRLA SUN LIFE MUTUAL FUND	Buy	1033015	1252	24 Oct 2025
EASTSPRING INVESTMENTS INDIA CONSUMER EQUITY OPEN LIMITED	Buy	319750	1252	24 Oct 2025
DOCON TECHNOLOGIES PRIVATE LIMITED	Sell	5332860	1252.03	24 Oct 2025
NEO APEX VENTURE LLP	Sell	354298	1252.81	24 Oct 2025
GRAVITON RESEARCH CAPITAL LLP	Sell	725235	1310.33	15 Oct 2025
GRAVITON RESEARCH CAPITAL LLP	Buy	725235	1311.66	15 Oct 2025

Thyrocare Technologies Ltd News

Thyrocare Cancels Q4 FY26 Earnings Conference Call

Thyrocare Technologies cancels its Q4 FY26 earnings conference call scheduled for May 07, 2026, citing unforeseen circumstances. A revised schedule will be announced in due course.

08 May 2026

companies

Thyrocare FY26: PAT Surges 81%, Board Approves Key Changes

Thyrocare FY26 PAT surged 81% to Rs. 162.85 crore on 21% revenue growth. Board approved Rs. 7 final dividend, new auditors, director changes, and Rs. 5.50 crore subsidiary investment.

07 May 2026

companies

Thyrocare FY26: PAT Surges 81%, Board Approves Key Changes

Thyrocare FY26 PAT surged 81% to Rs. 162.85 crore on 21% revenue growth. Board approved Rs. 7 final dividend, new auditors, director changes, and Rs. 5.50 crore subsidiary investment.

07 May 2026

companies

Thyrocare FY26: PAT Surges 81%, Board Approves Key Changes

Thyrocare FY26 PAT surged 81% to Rs. 162.85 crore on 21% revenue growth. Board approved Rs. 7 final dividend, new auditors, director changes, and Rs. 5.50 crore subsidiary investment.

07 May 2026

companies

Thyrocare FY26: PAT Surges 81%, Board Approves Key Changes

Thyrocare FY26 PAT surged 81% to Rs. 162.85 crore on 21% revenue growth. Board approved Rs. 7 final dividend, new auditors, director changes, and Rs. 5.50 crore subsidiary investment.

07 May 2026

companies

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800